Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase Ia/II multicenter study of JMT203 in cancer cachexia
CTR20240046Phase 2Active
- Sponsor
- Shanghai Jinmante Biotechnology Co., Ltd.
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of JMT203 in cancer anorexia-cachexia syndrome (CACS), sponsored by Shanghai Jinmante Biotechnology Co., Ltd.. Started May 2024; status: active.
02
Drugs
JMT203
03
Conditions
cancer anorexia-cachexia syndrome (CACS)
Beyond the preview
Go deeper on CTR20240046.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240046.